Branded vs compounded GLP-1s: how they differ in evidence, dosing, safety and cost

If you started looking into GLP-1 weight-loss medication in 2023 or 2024, you probably saw “compounded” semaglutide and tirzepatide everywhere, sold at flat monthly prices through telehealth sites. The words “branded” and “compounded” still get used as if one were simply the cheaper edition of the other. They are different kinds of product: they rest on different evidence, come in different formats, carry different safety records, and cost different amounts. This guide compares them on the things that matter to someone deciding, and explains briefly why the compounded market looks so different in 2026.

Branded vs compounded GLP-1: what is the actual difference?

A branded GLP-1 went through the full drug-approval process: its safety, effectiveness, manufacturing, and labeling were reviewed by the FDA. Wegovy and Zepbound are the branded products approved for chronic weight management, and Ozempic and Mounjaro are the same two molecules approved for type 2 diabetes. Wegovy is indicated, alongside a reduced-calorie diet and increased activity, for adults with obesity and adults who are overweight with at least one weight-related condition (Wegovy prescribing information, DailyMed). Zepbound carries a similar weight-management indication plus an approval for moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound prescribing information, DailyMed).

A compounded GLP-1 is a preparation made by a pharmacy or outsourcing facility. Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness or quality before they are marketed (FDA, concerns with unapproved GLP-1 drugs used for weight loss). Compounding has a real role in medicine; the FDA’s own framing is that a compounded drug may be appropriate when a patient’s medical need cannot be met by an approved drug. It is an individualized exception, not a generic. Compounded products are not generics, and the FDA lists a seller claiming its compounded drug is “the same as” an approved drug as a warning sign (FDA).

What does the research actually cover?

The weight-loss results people quote for semaglutide and tirzepatide come from large randomized trials of the approved products, which puts them in the strongest evidence tier: approved drugs, studied for their labeled use. In STEP 1, adults with overweight or obesity taking semaglutide 2.4 mg once weekly with a lifestyle program lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% on placebo (Wilding et al., NEJM 2021, PubMed). Half of the semaglutide group (50.5%) lost at least 15% of their weight, and 4.5% stopped treatment because of gastrointestinal side effects, versus 0.8% on placebo. In SURMOUNT-1, tirzepatide produced average weight changes of 15.0%, 19.5% and 20.9% at the 5 mg, 10 mg and 15 mg doses over 72 weeks, versus 3.1% on placebo (Jastreboff et al., NEJM 2022, PubMed). In 2026 the FDA approved a higher Wegovy HD dose of 7.2 mg after the STEP UP trial reported about 20.7% mean weight loss (FDA approval announcement).

None of those trials tested a compounded product. A pharmacy preparation may contain the same molecule, but its strength, purity, sterility and stability depend on that pharmacy, and no trial has measured how it performs. There is also an ingredient question. The FDA says some compounders have sold semaglutide as salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in the approved drugs, and that it has no information on whether they behave the same way (FDA). So the honest evidence statement for a compounded GLP-1 is: plausible by analogy to the molecule, untested as a product.

How do branded and compounded GLP-1s differ day to day?

The biggest day-to-day difference is how the dose gets measured. Branded products mostly come as fixed-dose devices. Wegovy is supplied as single-dose pens, single-dose syringes, a FlexTouch pen that delivers four 2.4 mg doses, and tablets (Wegovy prescribing information). Zepbound comes as single-dose pens or vials, and as a multi-dose vial or KwikPen that holds four weekly doses; the label tells vial users to use a new syringe and needle for every injection and a syringe that can measure a 0.5 mL or 0.6 mL dose, and to throw a multi-dose vial or KwikPen away 30 days after first use or after four weekly doses, even if medicine is left (Zepbound prescribing information). Single-dose Zepbound pens and vials are kept refrigerated but can sit at room temperature, up to 86°F, for a total of 21 days, which is useful to know for travel.

Compounded GLP-1s are often dispensed in multi-dose vials that the patient draws from with a syringe, and the concentration can differ from one pharmacy to the next. The FDA’s practical advice for those vials (FDA):

• Throw the vial away 28 days after first use, even if medicine remains and even if the compounder’s instructions say it lasts longer, because contamination risk rises after that.
• Use a new, sterile needle and syringe for every dose.
• Do not use any injectable GLP-1 that arrives warm or without enough cold packs; the FDA has received complaints of compounded products shipped that way.

What safety problems has the FDA seen with compounded GLP-1s?

The FDA has received reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded semaglutide, where patients measured the wrong amount or clinicians miscalculated the dose (FDA). It has also received reports tied to compounded semaglutide or tirzepatide prescribed above the labeled doses or stepped up faster than the label schedule, with symptoms including nausea, vomiting, diarrhea, abdominal pain and constipation.

As of May 31, 2026, the agency had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide (FDA). Two cautions apply to those numbers. A report does not prove the drug caused the event. And because state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events, the FDA says the true count is likely higher. Many of the reported events look like the known side effects of the approved drugs. The FDA has also found fraudulent “compounded” products whose labels name pharmacies that do not exist or that did not make them.

None of this means branded products are side-effect free. Nausea, diarrhea, vomiting and constipation are common on Wegovy and Zepbound too, and the labels carry serious warnings including pancreatitis, gallbladder disease and a boxed warning about thyroid C-cell tumors seen in rodents. Our GLP-1 side effects guide walks through them. The difference is that with a branded product the dose in the pen is the dose on the label.

Why are compounded GLP-1s harder to find in 2026?

Compounded semaglutide and tirzepatide spread widely because the branded products were in FDA-declared shortage, and that shortage has ended: the FDA determined the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage on February 21, 2025, and the wind-down windows for pharmacies closed in spring 2025 (FDA compounder policy). The FDA has also proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list (FDA announcement); the comment period ran to July 30, 2026 (Federal Register), and as of October 12, 2026 it is still a proposal. In March 2026 the FDA sent warning letters to 30 telehealth companies over misleading compounded GLP-1 marketing (FDA). For what compounded semaglutide is and the narrow cases where a prescriber may still use it, see our compounded semaglutide explainer.

How do you spot a risky GLP-1 seller?

The FDA publishes its own list of telehealth red flags, and it matches what tends to go wrong in practice. Be wary if a company (FDA):

• claims its compounded drug is the same as an FDA-approved drug;
• offers deep discounts or prices that seem too good to be true;
• sends medicine that looks different from what you received before or from what was pictured, or that arrives in broken packaging or without instructions;
• does not require a screening and a prescription from a licensed clinician;
• has no licensed clinician available to answer questions after the medicine arrives;
• ships labels with spelling errors, wrong pharmacy addresses, or a pharmacy name you suspect is fake.

Branded products have their own counterfeit problem: the FDA says counterfeit Ozempic has been found in the U.S. drug supply, and it urges buyers to use only state-licensed pharmacies (FDA). Products sold “for research purposes” or “not for human consumption” are a separate category again: the FDA says it has warned companies selling semaglutide and tirzepatide that way directly to consumers with dosing instructions.

How does honest online GLP-1 care work?

Getting a GLP-1 online in 2026 should start with a clinical evaluation, not a checkout page. A responsible program reviews your health history, confirms you fit the labeled picture (broadly obesity, or overweight with a weight-related condition, per the Wegovy and Zepbound labels), uses lab work where indicated, and only then decides whether a GLP-1 is appropriate and at what dose. GLP-1 medications are not controlled substances, so the federal in-person-exam rule for controlled drugs does not apply to them, but the prescriber must still be licensed in your state (HHS Telehealth: licensing across state lines). The FDA’s own advice to patients is simple: get the prescription from a clinician and fill it at a state-licensed pharmacy (FDA).

Good programs treat the prescription as a starting point. A GLP-1 is begun at a low dose and raised gradually to limit side effects, so follow-up and dose adjustment are part of the plan; our dosing and titration explainer shows the label schedules. For the full step-by-step on starting care online, see GLP-1 weight-loss treatment online in 2026, and if you are weighing the two molecules, read semaglutide vs tirzepatide.

Is branded GLP-1 medication more expensive than compounded?

Price is the main reason compounded versions became popular, so it deserves a straight answer. The very cheap flat monthly compounded fee is fading as that market shrinks, and the branded side has changed too: both manufacturers now sell self-pay cash programs well below list price. What actually moves your out-of-pocket cost on the branded side is whether your plan covers weight-management medication, whether you meet its prior-authorization criteria, and whether a manufacturer program applies. We break the current published numbers down in what a GLP-1 costs without insurance. When comparing, weigh the price against what you get: a fixed, labeled dose with trial evidence behind it versus a preparation whose strength and quality depend on one pharmacy. PeptideAgent’s GLP-1 hub also sets the approved drugs’ cash and insured prices next to their evidence and FDA status.

The bottom line

Branded and compounded GLP-1s share a molecule and little else. Branded Wegovy, Zepbound, Ozempic and Mounjaro are FDA-approved, come in fixed-dose formats, and have large trials behind them: about 15% average weight loss with semaglutide in STEP 1 and up to about 21% with tirzepatide in SURMOUNT-1. Compounded versions are not FDA-approved, have no trials of their own, are often measured by hand from multi-dose vials, and have been linked to dosing errors and hundreds of adverse event reports, likely an undercount. Since the shortages ended they are also much less available than they were in 2024. If you are choosing, start from the evidence and the dose you can trust, and let a licensed provider who evaluates you first decide what fits.